U.S. Markets open in 2 hrs 49 mins
  • S&P Futures

    3,428.00
    -4.50 (-0.13%)
     
  • Dow Futures

    28,098.00
    -36.00 (-0.13%)
     
  • Nasdaq Futures

    11,675.00
    -16.25 (-0.14%)
     
  • Russell 2000 Futures

    1,605.90
    +2.80 (+0.17%)
     
  • Crude Oil

    40.31
    +0.28 (+0.70%)
     
  • Gold

    1,920.90
    -8.60 (-0.45%)
     
  • Silver

    24.98
    -0.26 (-1.03%)
     
  • EUR/USD

    1.1844
    -0.0022 (-0.1895%)
     
  • 10-Yr Bond

    0.8160
    0.0000 (0.00%)
     
  • Vix

    29.30
    -0.05 (-0.17%)
     
  • GBP/USD

    1.3114
    -0.0030 (-0.2269%)
     
  • USD/JPY

    104.6450
    +0.0850 (+0.0813%)
     
  • BTC-USD

    12,967.01
    +1,910.00 (+17.27%)
     
  • CMC Crypto 200

    260.48
    +15.59 (+6.36%)
     
  • FTSE 100

    5,770.79
    -5.71 (-0.10%)
     
  • Nikkei 225

    23,474.27
    -92.73 (-0.39%)
     

A Look Into Healthcare Sector Value Stocks

Benzinga Insights
·2 mins read

The Meaning Behind Value Stocks

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.

Below is a list of notable value stocks in the healthcare sector:

  1. Bio-Rad Laboratories (NYSE: BIO) - P/E: 7.96

  2. Jaguar Health (NASDAQ: JAGX) - P/E: 0.02

  3. Opiant Pharmaceuticals (NASDAQ: OPNT) - P/E: 5.01

  4. OpGen (NASDAQ: OPGN) - P/E: 2.58

  5. Karuna Therapeutics (NASDAQ: KRTX) - P/E: 0.17

Bio-Rad Laboratories has reported Q2 earnings per share at 1.61, which has decreased by 15.71% compared to Q1, which was 1.91. Bio-Rad Laboratories does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

Most recently, Jaguar Health reported earnings per share at -0.44, whereas in Q1 earnings per share sat at -0.56. Jaguar Health does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

Opiant Pharmaceuticals has reported Q2 earnings per share at -0.05, which has increased by 87.5% compared to Q1, which was -0.4. Opiant Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

This quarter, OpGen experienced a decrease in earnings per share, which was -0.43 in Q1 and is now -0.49. OpGen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

Karuna Therapeutics has reported Q2 earnings per share at -0.65, which has decreased by 96.97% compared to Q1, which was -0.33. Karuna Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.